Cohort study evaluating efficacy and safety of gemcitabine for advanced or metastatic breast cancer (YCOG1005)
Not Applicable
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000013002
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Past history of gemcitabine administration. 2) Inflamatory breast cancer 3) Pulmonary fibrosis or interstitial pneumonia. 4) Heart failure or acute myocardiac infarction within 6 months. 5) Active infection. 6) Severe complications. 7) Severe drug allergy. 8) Severe psychiatric disorder. 9) Symptomatic brain betastasis 10) Double cancer. 11) Women who are pregnant, lactating or declined contraception. 12) Gastrointestinal perforation and severe fistula
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method